In conclusion, the current study demonstrated the clinical utility of targeted NGS with a focused hotspot cancer gene panel in NSCLCs, and identified activating somatic mutations in JAK2 and germline mutations in JAK3 with clinical implications inferred through integrative analysis of cancer genetic, genomic, and pharmacogenomic data. This evidence concerns the gene JAK3 and cancer.